Welcome back to the channel.

People have been asking me to talk about the two recent papers in the New England Journal of Medicine

about colorectal cancer screening.

We've got the blood-based cancer screening test by Garten.

We've got the stool DNA test by exact biosciences.

These are poised to become lucrative tests that doctors and hospitals administer to patients,

or I mean healthy people.

We'll see if they make anyone better off.

We'll talk about that in this video.

So first of all, we have to be clear.

Screening is about healthy people.

It's not about patients, so I may occasionally make that mistake as I talked through this video.

But we're taking healthy people.

We're extolling them to come in and participate in some preventive screening program

in the hopes that we're going to make them better off.

So let's talk about the history of colorectal cancer screening.

Let's talk about what we know about these two tests.

And let's talk about why I have some reservations about them.

So first, the history of color rectal cancer screening.

I mean, we have a number of modalities that have direct randomized control trial evidence

evaluating whether or not that screening lowers the rate of colorectal cancer death

and ultimately all-cause mortality.

...